Effect of Multimodal Prehabilitation on Reducing Postoperative Complications and Enhancing Functional Capacity Following Colorectal Cancer Surgery: The PREHAB Randomized Clinical Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 468 KB, PDF-dokument

  • Charlotte Johanna Laura Molenaar
  • Enrico Maria Minnella
  • Miquel Coca-Martinez
  • David Wouter Gerard Ten Cate
  • Marta Regis
  • Rashami Awasthi
  • Graciela Martínez-Palli
  • Manuel López-Baamonde
  • Raquel Sebio-Garcia
  • Carlo Vittorio Feo
  • Stefanus Johannes Van Rooijen
  • Jennifer Marijke Janneke Schreinemakers
  • Rasmus Dahlin Bojesen
  • Gögenur, Ismail
  • Edwin R. Van Den Heuvel
  • Francesco Carli
  • Gerrit Dirk Slooter

Importance: Colorectal surgery is associated with substantial morbidity rates and a lowered functional capacity. Optimization of the patient's condition in the weeks prior to surgery may attenuate these unfavorable sequelae. Objective: To determine whether multimodal prehabilitation before colorectal cancer surgery can reduce postoperative complications and enhance functional recovery. Design, Setting, and Participants: The PREHAB randomized clinical trial was an international, multicenter trial conducted in teaching hospitals with implemented enhanced recovery after surgery programs. Adult patients with nonmetastasized colorectal cancer were assessed for eligibility and randomized to either prehabilitation or standard care. Both arms received standard perioperative care. Patients were enrolled from June 2017 to December 2020, and follow-up was completed in December 2021. However, this trial was prematurely stopped due to the COVID-19 pandemic. Interventions: The 4-week in-hospital supervised multimodal prehabilitation program consisted of a high-intensity exercise program 3 times per week, a nutritional intervention, psychological support, and a smoking cessation program when needed. Main Outcomes and Measures: Comprehensive Complication Index (CCI) score, number of patients with CCI score more than 20, and improved walking capacity expressed as the 6-minute walking distance 4 weeks postoperatively. Results: In the intention-to-treat population of 251 participants (median [IQR] age, 69 [60-76] years; 138 [55%] male), 206 (82%) had tumors located in the colon and 234 (93%) underwent laparoscopic- or robotic-assisted surgery. The number of severe complications (CCI score >20) was significantly lower favoring prehabilitation compared with standard care (21 of 123 [17.1%] vs 38 of 128 [29.7%]; odds ratio, 0.47 [95% CI, 0.26-0.87]; P =.02). Participants in prehabilitation encountered fewer medical complications (eg, respiratory) compared with participants receiving standard care (19 of 123 [15.4%] vs 35 of 128 [27.3%]; odds ratio, 0.48 [95% CI, 0.26-0.89]; P =.02). Four weeks after surgery, 6-minute walking distance did not differ significantly between groups when compared with baseline (mean difference prehabilitation vs standard care 15.6 m [95% CI, -1.4 to 32.6]; P =.07). Secondary parameters of functional capacity in the postoperative period generally favored prehabilitation compared with standard care. Conclusions and Relevance: This PREHAB trial demonstrates the benefit of a multimodal prehabilitation program before colorectal cancer surgery as reflected by fewer severe and medical complications postoperatively and an optimized postoperative recovery compared with standard care. Trial Registration: trialregister.nl Identifier: NTR5947.

OriginalsprogEngelsk
TidsskriftJAMA Surgery
Vol/bind158
Udgave nummer6
Sider (fra-til)572-581
Antal sider10
ISSN2168-6254
DOI
StatusUdgivet - 14 jun. 2023

Bibliografisk note

Funding Information:
Conflict of Interest Disclosures: Dr Minnella reported personal fees from Dompé Farmaceutici as employee from June 2021. Dr Gögenur reported grants from Pharmacosmos, surgical grants for travelling and speakers fees from Intuitive, and served on the advisory board for Ethicon outside the submitted work. Dr Slooter reported grants from KWF-Kankerbestrijding, Dutch Cancer Society, and Johnson & Johnson and nonfinancial support from FrieslandCampina and Philips during the conduct of the study. No other disclosures were reported.

Funding Information:
Funding/Support: Máxima Medical Center received funding from the Dutch Cancer Society and Johnson & Johnson . FrieslandCampina provided the protein supplements for Máxima Medical Center, Hospital Clínic de Barcelona, S. Anna University Hospital, Mútua Terrassa University Hospital, Amphia and Bernhoven. Philips loaned accelerometers to the Dutch centers. McGill University Health Center received funding from the Peri Operative Program Charitable Foundation and the Montreal General Hospital Department of Anesthesia . Whey protein supplements were provided by Immunotec . Zealand University Hospital received charitable donations from the Beckett Foundation , Axel Muusfelts Foundation , Einar Willumsens Foundation , and Dagmar Marchalls Foundation .

Publisher Copyright:
© 2023 American Medical Association. All rights reserved.

ID: 370369078